دورية أكاديمية
Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability.
| العنوان: | Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability. |
|---|---|
| المؤلفون: | Xavier FD; Hospital Universitário de Brasília-Universidade de Brasília/Ebserh, Brasília, DF, Brazil.; Hospital DF Star, Oncologia D'Or, Rede D'Or, Brasília, DF, Brazil., Farias DLC; Hospital A Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil., Neto AEH; Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil., Ribeiro GN; Clínica Hematológica/Grupo Oncoclinicas, Belo Horizonte, MG, Brazil., Araujo MAS; Universidade Federal da Bahia, Salvador, BA, Brazil.; Instituto D'Or de Pesquisa e Ensino, IDOR, BA, Brazil., Carneiro TX; Universidade Estadual do Pará, Belém, PA, Brazil., Baiocchi OCCG; Universidade Federal de São Paulo, São Paulo, SP, Brazil.; Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil. |
| المصدر: | Oncotarget [Oncotarget] 2023 Dec 12; Vol. 14, pp. 977-994. Date of Electronic Publication: 2023 Dec 12. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Electronic Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مواضيع طبية MeSH: | Hodgkin Disease*/drug therapy , Hodgkin Disease*/pathology , Immunoconjugates* , Hematopoietic Stem Cell Transplantation*, Adolescent ; Young Adult ; Humans ; Brazil ; Brentuximab Vedotin/therapeutic use |
| مستخلص: | Classic Hodgkin lymphoma (CHL), which accounts for 90-95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10-15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted mainly of salvage chemotherapy, in many cases followed by high-dose chemotherapy and autologous stem-cell transplantation. However, improved understanding of the pathobiology of CHL, coupled with the introduction of novel agents, has markedly changed the treatment landscape in the past decade. Although refractory or relapsed CHL continues to be challenging, the therapeutic landscape is undergoing profound changes brought about by novel agents, particularly brentuximab vedotin and immunotherapy. In this review, we discuss the most salient treatment options for adult patients with refractory or relapsed CHL, with a special focus on the Brazilian healthcare setting, which is constrained by inherent characteristics of this system. In the attempt to balance efficacy, safety and tolerability, practicing physicians must rely on clinical trials and on results from real-world studies, and use their own point of view and experience, as well as patient characteristics and previous therapy, to make treatment decisions for refractory or relapsed CHL. |
| References: | Br J Haematol. 2020 May;189(3):e86-e90. (PMID: 32048731) J Clin Oncol. 2016 Jun 10;34(17):2028-36. (PMID: 27114593) Blood. 2015 Feb 19;125(8):1236-43. (PMID: 25533035) Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. (PMID: 29796651) Hematol Oncol. 2022 Feb;40(1):31-39. (PMID: 34694649) Lancet. 1993 Apr 24;341(8852):1051-4. (PMID: 8096958) J Clin Oncol. 2018 May 10;36(14):1428-1439. (PMID: 29584546) J Clin Oncol. 2010 Sep 20;28(27):4199-206. (PMID: 20713848) Ann Oncol. 2019 Apr 1;30(4):612-620. (PMID: 30657848) Br J Haematol. 2012 Jun;157(5):543-52. (PMID: 22429186) Blood. 2018 Apr 12;131(15):1666-1678. (PMID: 29500174) Lancet Oncol. 2016 Sep;17(9):1283-94. (PMID: 27451390) Blood Adv. 2018 Sep 11;2(17):2226-2229. (PMID: 30190282) Blood. 2021 Aug 12;138(6):427-438. (PMID: 33827139) Oncotarget. 2017 Oct 9;8(54):92978-92988. (PMID: 29190971) Blood. 2018 Apr 12;131(15):1689-1697. (PMID: 29500170) J Clin Oncol. 2005 Dec 20;23(36):9208-18. (PMID: 16314615) Hematol Oncol. 2018 Feb;36(1):189-195. (PMID: 28643458) N Engl J Med. 2010 Aug 12;363(7):640-52. (PMID: 20818855) Clin Lymphoma Myeloma. 2009 Dec;9(6):449-54. (PMID: 19951885) Leuk Lymphoma. 2021 Dec;62(14):3320-3332. (PMID: 34323643) Blood. 2017 May 4;129(18):2471-2478. (PMID: 28270452) Medicine (Baltimore). 2015 Jun;94(25):e987. (PMID: 26107683) Br J Haematol. 2017 Nov;179(3):471-479. (PMID: 28857136) Cancer. 2020 Feb 15;126(4):757-764. (PMID: 31714588) Hematol Oncol. 2013 Mar;31(1):34-40. (PMID: 22473680) Oncotarget. 2017 May 23;8(53):91703-91710. (PMID: 29207679) N Engl J Med. 2018 Jan 25;378(4):331-344. (PMID: 29224502) Leuk Lymphoma. 2018 Jun;59(6):1413-1419. (PMID: 29045163) J Clin Oncol. 2013 Feb 20;31(6):684-91. (PMID: 23182987) J Clin Oncol. 2019 Aug 10;37(23):1997-2007. (PMID: 31112476) Blood. 2018 Apr 12;131(15):1654-1665. (PMID: 29500175) Lancet. 2015 May 9;385(9980):1853-62. (PMID: 25796459) Ann Oncol. 2017 Oct 01;28(10):2496-2502. (PMID: 28961828) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) BMC Cancer. 2020 Nov 10;20(1):1088. (PMID: 33172440) J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753) Leuk Lymphoma. 2018 Sep;59(9):2113-2120. (PMID: 29334819) Front Oncol. 2022 Jan 21;11:796270. (PMID: 35127505) Cancers (Basel). 2021 Jul 26;13(15):. (PMID: 34359646) Am Soc Clin Oncol Educ Book. 2019 Jan;39:477-486. (PMID: 31099645) Blood. 2016 Sep 22;128(12):1562-6. (PMID: 27432875) Blood Cancer J. 2019 Dec 11;9(12):100. (PMID: 31827067) Lancet Haematol. 2021 Jun;8(6):e410-e421. (PMID: 34048680) Ann Hematol. 2018 Oct;97(10):1817-1824. (PMID: 30054707) JAMA Oncol. 2020 Jun 1;6(6):872-880. (PMID: 32352505) N Engl J Med. 2011 Jul 21;365(3):203-12. (PMID: 21774708) Br J Haematol. 2018 Nov;183(3):400-410. (PMID: 30168134) Int J Cancer. 2018 Mar 1;142(5):883-890. (PMID: 29023692) CA Cancer J Clin. 2020 Jan;70(1):31-46. (PMID: 31661164) Crit Rev Oncol Hematol. 2016 Aug;104:65-70. (PMID: 27279289) Leuk Lymphoma. 2016 May;57(5):1074-82. (PMID: 26374099) J Clin Oncol. 2009 Nov 10;27(32):5390-6. (PMID: 19738111) Cancer. 2015 Oct 1;121(19):3515-24. (PMID: 26058564) Rev Saude Publica. 2010 Aug;44(4):620-8. (PMID: 20676553) CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946) Blood. 2021 Aug 19;138(7):520-530. (PMID: 33889927) Eur J Haematol. 2017 Dec;99(6):553-558. (PMID: 28949403) J Clin Oncol. 2021 Oct 1;39(28):3097-3103. (PMID: 34428096) Lancet Oncol. 2013 Dec;14(13):1348-56. (PMID: 24239220) Curr Hematol Malig Rep. 2021 Feb;16(1):1-7. (PMID: 33409966) Haematologica. 2021 Apr 01;106(4):1129-1137. (PMID: 32273476) Hematol Oncol. 2021 Feb;39(1):134-136. (PMID: 32881003) Blood. 2021 Mar 11;137(10):1318-1326. (PMID: 32992341) Lancet Oncol. 2021 Apr;22(4):512-524. (PMID: 33721562) Cancer. 2006 Jan 15;106(2):353-60. (PMID: 16329112) Oncologist. 2016 Dec;21(12):1436-1441. (PMID: 27486201) Cancer. 1993 May 1;71(9):2823-7. (PMID: 7682152) Leuk Lymphoma. 2019 Jun;60(6):1389-1398. (PMID: 30507313) Oncologist. 2019 Jul;24(7):955-962. (PMID: 30568021) Blood. 2018 Dec 20;132(25):2639-2642. (PMID: 30266774) N Engl J Med. 2022 Jul 28;387(4):310-320. (PMID: 35830649) Crit Rev Oncol Hematol. 2015 Sep;95(3):359-69. (PMID: 25964164) J Clin Oncol. 2017 Jul 1;35(19):2125-2132. (PMID: 28441111) Radiat Oncol. 2006 Oct 02;1:38. (PMID: 17014708) Blood. 2012 Jul 19;120(3):560-8. (PMID: 22510871) Rev Assoc Med Bras (1992). 2016 Oct;62 Suppl 1:34-38. (PMID: 27982313) Cancer Res. 1967 Jul;27(7):1258-63. (PMID: 4952914) Haematologica. 2013 Apr;98(4):611-4. (PMID: 23065511) Br J Haematol. 2016 Dec;175(5):860-867. (PMID: 27649689) Br J Haematol. 2019 Jan;184(2):202-214. (PMID: 30239982) Blood. 2019 Jul 4;134(1):22-29. (PMID: 30952672) Lancet Haematol. 2021 Aug;8(8):e562-e571. (PMID: 34329577) Lancet Oncol. 2018 Feb;19(2):257-266. (PMID: 29276022) Rev Bras Hematol Hemoter. 2011;33(1):10-4. (PMID: 23284236) Haematologica. 2003 May;88(5):522-8. (PMID: 12745271) Leuk Lymphoma. 2020 Nov;61(11):2630-2637. (PMID: 32684056) Lancet. 2002 Jun 15;359(9323):2065-71. (PMID: 12086759) Hematol Oncol. 2019 Aug;37(3):310-313. (PMID: 30847943) Lancet. 2021 Oct 23;398(10310):1518-1527. (PMID: 33493434) Int J Cancer. 2007 Feb 15;120(4):875-9. (PMID: 17131320) J Clin Oncol. 2010 Dec 1;28(34):5074-80. (PMID: 20975066) Cancer Epidemiol. 2021 Dec;75:102048. (PMID: 34700284) J Clin Oncol. 2012 Jun 20;30(18):2183-9. (PMID: 22454421) Biol Blood Marrow Transplant. 2020 Aug;26(8):1534-1542. (PMID: 32068094) Eur J Cancer. 2017 Aug;81:45-55. (PMID: 28601705) Biol Blood Marrow Transplant. 2017 Apr;23(4):705-707. (PMID: 28108270) Ann Hematol. 2020 Nov;99(11):2565-2576. (PMID: 32507911) J Clin Oncol. 2016 Apr 10;34(11):1175-81. (PMID: 26712220) Pediatr Blood Cancer. 2007 Aug;49(2):139-44. (PMID: 16642484) Blood. 2018 Apr 12;131(15):1698-1703. (PMID: 29500171) Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72. (PMID: 17084370) Front Pharmacol. 2020 Jul 30;11:1128. (PMID: 32848747) Cancer Epidemiol. 2020 Feb;64:101660. (PMID: 31877471) Oncol Rep. 2002 Mar-Apr;9(2):439-42. (PMID: 11836623) Blood. 2015 Nov 26;126(22):2452-8. (PMID: 26582374) J Clin Oncol. 2016 Nov 1;34(31):3733-3739. (PMID: 27354476) Blood. 2018 Jul 5;132(1):40-48. (PMID: 29703778) Hematol Oncol. 2021 Oct;39(4):498-505. (PMID: 34171130) J Cancer. 2019 Aug 28;10(21):5041-5048. (PMID: 31602255) J Hematol Oncol. 2014 Mar 19;7:24. (PMID: 24642247) N Engl J Med. 2015 Jan 22;372(4):311-9. (PMID: 25482239) Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):264-73. (PMID: 26826029) |
| فهرسة مساهمة: | Keywords: brentuximab vedotin; drug therapy; hodgkin lymphoma; nivolumab; pembrolizumab |
| المشرفين على المادة: | 0 (Immunoconjugates) 7XL5ISS668 (Brentuximab Vedotin) |
| تواريخ الأحداث: | Date Created: 20231212 Date Completed: 20231216 Latest Revision: 20231216 |
| رمز التحديث: | 20231218 |
| مُعرف محوري في PubMed: | PMC10715043 |
| DOI: | 10.18632/oncotarget.28541 |
| PMID: | 38085126 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.28541 |